Navigation Links
Cure For Pompe Disease

Pompe disease is a rare inherited enzyme deficiency that destroys muscles and can kill infants at a very young age. Myozyme is a drug developed by Genzyme// to treat this disease. Genzyme, a biotechnology company in Cambridge, Mass said that it has spent more than $500 million since 1998 to develop Myozyme.

It has also received incentives provided by the federal government to develop medicines against such disease collectively called orphans disease. The drug after passing through a variety of tests and trails has won the federal approval to sell the drug in the market. Genzyme officials said that the dug Myozyme, would cost about $200,000 to $300,000 a year. The disease incidence is less than 10000 people and they are all grateful for Genzyme's drugs. Genzyme said that it will provide the drug free of cost to those who cannot pay for it. During the clinical trail from 2003-05 the drug was administered to 18 infants.

They all lived until they were at least 18 months old, or about a year after starting treatment, and most are still alive today. The warning on the drug label says that Myozyme can also cause life-threatening anaphylactic or allergic reactions. Dr. David Meeker, president of the Genzyme division that developed Myozyme said that a new blood test was offered to diagnose the disease rapidly which could lead to earlier treatment with better outcome. But further tests are necessary to determine the effect of the drug against Pompe disease that begins later in childhood or in adulthood.


'"/>




Page: 1

Related medicine news :

1. Transdermal HRT not cardioprotective in postmenopausal women with Coronary Artery Disease
2. Vitamins-The answer to Heart Disease?
3. Link between Constipation and Parkinsons Disease
4. Levels Of Blood Proteins May Help Heart Disease Care
5. New Drug PP188 Helps Sickle Cell Disease
6. Gene Treatment for Heart Disease
7. Legume Consumption Can Cut Heart Disease Risk
8. Link Between Infection And Heart Disease
9. Celiac Disease in Type 1 Diabetes
10. Shunt for Alzheimers Disease
11. High iron levels may cause Cardiovascular Disease in women
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/12/2017)... , ... October 12, 2017 , ... ... to meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s ... experts and tested to meet the highest standard. , These products are ...
(Date:10/12/2017)... ... 12, 2017 , ... The American College of Medical Informatics (ACMI) will present ... the Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium ... Collen, a pioneer in the field of medical informatics, this prestigious award is presented ...
(Date:10/12/2017)... Rockville, Maryland (PRWEB) , ... October 12, 2017 ... ... a magnetic drug delivery system that we intend to develop to enable prevention ... regimens can lead to severe hearing loss, especially in pediatric patients. For cisplatin, ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a ... of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners ... October 11, 2017. , The annual award competition recognizes editorial and design excellence across ...
(Date:10/12/2017)... , ... October 12, 2017 , ... On Saturday, October ... treadmill relay – Miles by Moonlight to raise money for the American Heart Association ... more. , Teams will work together to keep their treadmills moving for 5 ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... , Sept. 25, 2017   Montrium ... Master File solutions, today—from the IQPC Trial Master ... , NL)—announced that EastHORN Clinical Services has ... clinical programs and TMF management. EastHORN, a leading ... eTMF platform to increase transparency to enable greater ...
(Date:9/19/2017)... -- HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy ... team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D ...
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017 ... performance ratings for global supply chains, has published the first annual edition ... CSR performance of more than 20,400 companies evaluated by EcoVadis, based on ... 2015 and 2016. ... EcoVadis Global CSR Risk & Performance Index ...
Breaking Medicine Technology: